Insulet Corporation
PODD 6Price and target zones价格与目标区间
In the buy zone在买入区间内
What the company does公司做什么
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
The company sells its products to end-users through the pharmacy channel; and independent distributors.
Read the full description查看完整介绍
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Company facts公司资料
- Founded成立时间
- 2000
- Headquarters总部
- Acton, Massachusetts
- Employees员工人数
- 5,400
- Industry行业
- Medical Devices
- Country国家
- United States
Investment thesis投资逻辑 from the watchlist来自关注列表
Would upgrade on
- ANALYZED 9/10 — ACCUMULATE, in entry band. Omnipod razor/blade; NOT a GLP-1 story — 2 device corrections + a Type-2 retention guide-cut, both fixable/datable. Real growth re-rate (fwd EPS > trailing). FV $160-200, entry $130-150. Trim 28x fwd.
🟢 9/10 分析——增持，处于入场区间内。 Omnipod 剃刀-刀片模式；不是 GLP-1 概念股——两次设备召回加一次 2 型糖尿病留存率指引下调，两者都可修复、有明确时间点。 真实的增长重估（前瞻每股收益高于历史）。 公允价值 $160-200，入场 $130-150。 减持 28x fwd。
Historical results历史业绩 past fiscal years — these values do not change过去财年——这些数值不会变动
Profit margins利润率 the share of revenue that stays as profit营收中留存为利润的比例
of every $1 of revenue每 $1 营收中的占比
- Return on equity净资产收益率
- 26%
- Revenue growth营收增长
- +24%
Competitive advantages竞争优势 from the thesis and the reports来自投资逻辑和报告
- Omnipod razor/blade; NOT a GLP-1 story — 2 device corrections + a Type-2 retention guide-cut, both fixable/datable.
- Break: a 3rd quality correction, or Type-2 retention proves to be GLP-1 substitution (Q4 call).
- The pitfall pattern-console-lock-in-is-symmetric (razor/blade console economics are symmetric — the same friction that protects an incumbent during a short outage locks it out once a rival's console lands with a customer) was reviewed.
- The real switching costs are prescription/insurance authorization, pharmacy-channel fulfillment habits, and patient/physician familiarity — stickier to friction, less like a hard capital-equipment lock.
- Flagged as a moat nuance below, not a literal application of the pattern. 1.